Register for Session 4 of our webinar series to benefit from an interactive session where you can ask your questions to an expert advanced therapies panel!
Join us on 7th June to explore how to know if advanced therapies are the right fit for your rare condition and group, what needs to be considered before getting involved and the common challenges faced throughout the development pathway.
Please note: Session 4 must be signed up for separately using its specific Eventbrite page!
The Resources Hub is a 100% free e-learning platform that is full of exclusive content that guides patient groups through every stage of their rare disease journey.
REMEDi4ALL is a new flagship EU-funded research initiative to drive the repurposing of medicines across the UK and Europe. We’re one of 24 UK and European partners working to repurpose medicines to treat some of the world’s rarest and most neglected conditions.
Bear with us while we make this website mobile-friendly
We understand there will be mobile navigation issues to resolve on our new site. Please bear with us as we work on them.
Ensuring that no one faces their rare journey alone
Beacon (formerly known as Findacure) is a UK-based charity that is building a united rare disease community with patient groups at its heart. We envision a world in which no one faces their rare journey alone. Our charity upskills rare disease patient groups through trainings, guided programmes, community projects and research initiatives. We help these groups maximise their impact and deliver change for the world’s often neglected rare disease patients.
Rare diseases affect between 3.5% (263 million) and 5.9% (446 million) of the global population. Sadly, this population struggles to receive a diagnosis, treatment or meet another with the same condition. Patient groups are a lifeline for those living with a rare disease. They provide emotional support and advice for day-to-day living. Patient groups are the impetus behind new care pathways and treatments.
We are here to help those groups be the best that they can be.
Ensuring that no one faces their rare journey alone
Beacon (formerly known as Findacure) is a UK-based charity that is building a united rare disease community with patient groups at its heart. We envision a world in which no one faces their rare journey alone. Our charity upskills rare disease patient groups through trainings, guided programmes, community projects and research initiatives. We help these groups maximise their impact and deliver change for the world’s often neglected rare disease patients.
Rare diseases affect between 3.5% (263 million) and 5.9% (446 million) of the global population. Sadly, this population struggles to receive a diagnosis, treatment or meet another with the same condition. Patient groups are a lifeline for those living with a rare disease. They provide emotional support and advice for day-to-day living. Patient groups are the impetus behind new care pathways and treatments.
We are here to help those groups be the best that they can be.
Our in-person, virtual and on-demand trainings give patient organisations the tools and confidence they need to form, grow and professionalise.
Rare Community
Our community projects unite patient groups, researchers, healthcare professionals and industry representatives to encourage collaborations, advancing the field of rare diseases.
Rare disease research
Our drug repurposing conference and research projects aim to bring crucial new treatments to the world’s rarest patients.
Our community projects unite patient groups, researchers, healthcare professionals and industry representatives to encourage collaborations, advancing the field of rare diseases.
As a carer of a son diagnosed with ring 20 syndrome, Allison Watson increasingly felt the need for a patient group that would provide support and advice to help families and patients cope with the condition.
Bhavna’s world changed forever when her seven-year-old son, Ethan, was diagnosed with Stargardt’s: an inherited, condition that slowly leads to sight loss.
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Our Project Manager, Philippa (Phil) has officially left Beacon to pursue her next chapter: teaching English abroad! Read Phil’s leaving blog now and wish her well on her adventures!
As a carer of a son diagnosed with ring 20 syndrome, Allison Watson increasingly felt the need for a patient group that would provide support and advice to help families and patients cope with the condition.
Bhavna’s world changed forever when her seven-year-old son, Ethan, was diagnosed with Stargardt’s: an inherited, condition that slowly leads to sight loss.
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Beacon is delighted to announce our next masterclass - Building Confidence: how to be the best leader for your communityThis masterclass is for rare disease patient group leaders who want […]
Our Project Manager, Philippa (Phil) has officially left Beacon to pursue her next chapter: teaching English abroad! Read Phil’s leaving blog now and wish her well on her adventures!
Click on the link which best describes you. We’ll point you to our most relevant pages and additional places for support within the rare disease community.
Click on the link which best describes you. We’ll point you to our most relevant pages and additional places for support within the rare disease community.
At Beacon, we want to ensure that no one walks their rare journey alone. To achieve this, rare diseases must be viewed under one, united umbrella by patient groups, researchers and policymakers alike. Our work encourages patient organisations to work together for the benefit of all rare conditions. The pharmaceutical industry and research sectors must recognise the importance of the patient voice.
Work with us to make this happen! Discover our corporate giving and community fundraising opportunities to learn how you can bring hope to millions of people around the world. Each pound you give will help to break the isolation experienced by rare patients around the world.
“Patient groups like Beacon provide critical information and resources to help the rare disease community get closer to treatments for devastating illnesses.”
“There has been advice about how to become a charity, how to fundraise, how to work with researchers. They think of everything!”
Support our mission
At Beacon, we want to ensure that no one walks their rare journey alone. To achieve this, rare diseases must be viewed under one, united umbrella by patient groups, researchers and policymakers alike.
Our work encourages patient organisations to work together for the benefit of all rare conditions. The pharmaceutical industry and research sectors must recognise the importance of the patient voice.
Work with us to make this happen! Discover our corporate giving and community fundraising opportunities to learn how you can bring hope to millions of people around the world. Each pound you give will help to break the isolation experienced by rare patients around the world.
It’s been and exhausting but exhilarating week, the highlight being attending RAREsummit19 at the Wellcome Genome Campus organised by the Cambridge Rare Disease Network on Monday 23rd Sept 19.
From showcasing our latest poster on our Ring20 stand, to presenting to a packed auditorium of 250 people, to the numerous leads to follow-up in terms of future collaboration – and to top it all I made the BBC News that evening! (check out the video: BBC News video clip).
It was an early start, driving up to Cambridge from Essex to arrive for 8am to put up our new poster and arrange the stand.
The theme we chose for our our poster was ‘Solving the puzzle’ of diagnosis. r(20) syndrome is perceived as under-diagnosed and likely misdiagnosed. A big part of the problem is the lack of awareness among pediatricians and neurologists of the signs and symptoms of r(20) which are very similar to other rare epilepsies such as Lennox Gastaut Syndrome (LGS) because of the slow spike wave EEG pattern and prolonged non-convulsive status epilepticus (NCSE). Standard panel tests for genetic epilepsy DO NOT currently detect ring chromosomes, so unless the treating physician knows to request a karyotype to test for chromosomal mosaicism (and to submit at least 50-100 cells – which is more than usually submitted), then the chances of an r(20) diagnosis being made are actually very slim. We suspect that a proportion of patients with other epilepsy diagnosis e.g. LGS may actually have r(20), but have never had the diagnostic testing to prove this…
DID YOU KNOW that ring chromosomes occur 1 in 50,000 live births? So, why are there only 150 cases of r(20) cited in medical literature worldwide – we would expect a lot more…
Why is diagnosis important?
Diagnosis can lead to different options for care and treatment. Very topically at the moment we are all hearing about Cannabidiol (Epidyolex) in the news which is licensed in the US, and has just this week been approved by the EMA in Europe. Whilst there’s some way to go for each European country to determine whether to offer Epidyolex under its own national health system, if and when it is approved for use it will initially only be available to those with a diagnosis of Dravet Syndrome or LGS as an add-on to Clobazam. It may be quite some time before this treatment can be prescribed off-label to other complex rare epilepsy patients such as those with r(20) syndrome – and yet we share the same symptoms as many LGS patients?I was privileged to be offered a spot on the patient panel, kicking off the main proceedings of the day. Nervous, but confident in my subject matter I took to the stage and waited for my slot to speak.
The panel theme was Patient groups partnering in the drug development process. Something for everyone? and my lovely mentor Ana Mingorance (pictured here) was facilitating. Ana was appointed to me by EURORDIS as part of the leadership program I’m following this year and this was the first face-to-face meeting for us, Ana is a neuroscientist and has a background working in drug discovery and development in the pharmaceutical industry. She has worked with the Dravet Foundation in Spain and now works with the LouLou Foundation (which represents CDKL5 another rare epilepsy).My presentation centered around the fact that as a patient group representing an ultra-rare disease we are at the very start of the drug development journey – in fact, we have some way to go to even take our first steps since we have a limited no. of diagnosed cases, no patient registry, very little research, no bio-markers and have never been involved in a clinical trial. Yet, I turn this on its head and suggest that we are ripe for opportunity! I explained that, even as an ultra-rare disease patient organisation we can still get involved and raise the profile of the disease we represent, which is exactly what I’ve done through my engagement in EpiCARE the European Reference Network (ERN) for rare and complex epilepsies. By simply participating in the discussions and being present, r(20) is getting heard and recognised and I know for a fact that in the regular Clinical Patient Management System (CPMS) sessions – where neurologists from across Europe discus the most complex cases in a virtual consultation session – recently several cases have been suggested to check for an r(20) diagnosis. Even if they’re tested and found not to be r(20), that’s progress! We’re also working on several initiatives to produce educational materials for clinicians and patient families as part of EpiCARE – this wouldn’t have happened if I wasn’t volunteering for them.
My talk was recorded so I’ll share this as and when it becomes available.
Immediately after my presentation was a much-needed coffee break, however I was approached immediately by two representatives from Illumina ( the company behind the super-computers who sequence the human genome on campus as part of the 100,000 genomes project). There interest was piqued by my talk and they want to talk more to see if they can help us. Jillian Hastings-Ward Chair of UK #Genomes100k Participant Panel popped by my stand to say hello too – we met a couple of months ago when I last spoke at the Sano Genetics event. Next up was Mary Bythell Head of Rare Disease Registration from the National Congenital Anomalies and Rare Disease Registry Service (NCARDRS). We’d previously been in contact with NCARDRS and found that they hadn’t any records yet of r(20) patients, however now they’re interested in speaking to us about how we can change this and we’ve already lined up a call to talk about next steps.
For those of you who don’t know about these 3 organisations, they form the triad of services in the UK created as a result of the UK Rare Disease Strategy 2013-2020, which is due to be renewed shortly. These are key players in genomic sequencing/diagnosis (in which the UK are world leaders), rare disease registration and access to research for rare disease patients. We really want r(20) to be on their radar and we’re working hard to make this happen. (In fact we are also in conversation with NIHR Bioresource Unit to determine how we might get an r(20)/ring chromosome cohort on their books.)
In the afternoon we were challenged to participate in a hackathon introduced by Baroness Nicola Blackwood, Parliamentary Under Secretary of State at the Dept of Health and Social Care. Baroness Blackwood has a rare disease herself and so is a positive advocate for our community. We broke out into groups to cover different topics including diagnosis, care coordination, access to research, cost of treatment and patient empowerment. There was some lively discussion and I shout out for the ultra-rare diseases (including r(20)) where simply the basic needs must be met first and that the onus should not be on small ‘kitchen table’ patient organisations to fund these activities e.g. having a record of patients so its known how many people are affected and how they can be contacted for research participation. The results were discussed as a whole group and the key themes will be written up and presented back to Baroness Blackwood later this year, as input to the next UK Rare Disease Strategy. (This is the 3rd event where I have contributed to input to this strategy in a week, as I’ve also been working as part of the rare disease sub-group for the Neurological Alliance as well as attending an event organised by Genetic Alliance UK, so as a patient group we’re definitely having our say and contributing to the final outcomes!)
There were many friends and acquaintances to catch up with at RAREsummit19 including Rare Revolution, Findacure, AKU Society, fellow EPAG representatives including from Pitt Hopkins, Jelena Aleksic from Sparkbio, Patrick Short from Sano Genetics…the list goes on. Although there are reported to be 8,000+ rare diseases the patient community is quite tight and strong and we all support each other like one big family. Ron Jortner (from Masthead Biosciences and Trustee for CamRARE) recently contacted me about r(20) and included us in one of his talks – he’d now like to follow-up with a potential opportunity for us to present to pharma companies in the near future.
One of the organisers, Joanna Segeith (from Biosynetix) got in touch before the event and we had a brief dialog on the day. Joanna has an idea for a research opportunity for ‘basket’ trials and we’re going to be speaking to Prof Helen Cross re how the 3 of us might take this idea forwards.
Just getting out there and talking about r(20) syndrome really does get us noticed. Perhaps next time one of you will join me as I could really use the support.
You may be thinking that many of the opportunities from this event are UK based, but we have to take small steps and start somewhere. My work with EpiCARE means we’re also working at a European level. Next stop to conquer the world – one step at a time…eh?
I’ll keep you posted on any developments. This really is where the magic happens!
To mark Rare Diseases Day on Thursday Leigh meets Jo Balfour from the Cambridge Rare Diseases Network, Dr Thomas Hiemstra from the University of Cambridge Clinical Trials Unit and Allison who co-founded the patient support group Ring20 Research and Support UK after her son was diagnosed with the rare disease.
Cambridge Rare Disease Network is gearing up for its 4th RAREsummit on September 23 at the Wellcome Genome Campus and excitement is building for what promises to be an innovative event challenging the status quo.
The organisers don’t do things by halves and from the outset have provided a platform for an impressive collection of hard-hitting speakers from the Cambridge Cluster and University alongside European and US experts.
The late Professor Stephen Hawking, Cambridge’s best-known rare disease advocate, shared his own personal story at the inaugural Cambridge Rare Disease Summit. Professor Hawking was diagnosed with motor neuron disease at 21 and was told science had no answers.
He went on to live a long and productive life with the support of medical and technological advances and Cambridge Rare Disease Summits continue to drill down into how to make this a reality for all 3.5 million Britons affected by rare disease.
With more than 7000 rare diseases already identified, we each face a one in 17 chance of developing one during our lifetime yet, disturbingly, only five per cent of these have an approved treatment.
Recent advances in genetics, genomic medicine and technologies – such as gene-editing and CRISPR – mean that scientists are better placed than ever before to diagnose, treat and potentially cure rare genetic disorders.
Likewise, assistive technologies are improving accessibility and independence and Artificial Intelligence is opening up new opportunities for faster and cheaper therapeutic possibilities.
This year’s RAREsummit will be true to form with a selection of high calibre speakers. Dr Jonathan Milner, co-founder and deputy chairman of Abcam and biotech entrepreneur, will deliver the welcome address.
A keen supporter of CamRARE and its ambitions from the outset, he has been involved as a speaker, company sponsor, a significant donor through his foundation The Evolution Education Trust, and most recently joined CamRARE’s board of trustees.
Joining Jonathan on stage are Cambridge healthcare pioneers Dr Andy Richards and Dr David Brown, co-founder and chair of rare disease drug-repurposing company Healx. They will share their vision of 21st century digital health where technologies empower patients to manage their own health, find treatments and be connected.
Local pharmaceutical company representatives Steve Rees of AstraZeneca and Neil Dugdale of Sobi, a pioneering Granta Park based orphan drug company, will join leading rare disease patient advocate Dr Nick Sireau, founder of the AKU Society and Findacure to explore industry & patients’ current views and future vision of the drug development process.
Seeking to disrupt the ‘them and us’ relationship dynamic, RAREsummit’s programme will see CEOs of rare disease advocacy groups such as Emily Crossley of Duchene UK and Dr Paul Wicks from PatientLikeMe, share the stage with industry, academia and healthcare experts to showcase drug development, technology and healthcare projects where collaboration with them has prospered.
The aim of the agenda is to discover more about rare diseases and for each delegate to take home a toolkit of strategies that can be applied to their own working relationships and projects.
CamRARE is a charity formed in 2015 as a strategic hub aimed at accelerating scientific, clinical and social innovation towards effective health care for patients affected by rare diseases.
Co-founded by Dr Tim Guilliams, CEO of Healx, CamRARE has the same mission to transform the lives of rare disease patients.
Guilliams says: “There’s already not enough resources, not enough data yet so many challenges that the only way forward is to collaborate.”
It is this vision which sparked the idea of developing a network complementary to existing organisations such as One Nucleus, Innovation Forum and Cambridge Network – building an active community of individuals, organisations and companies with the collective capacity to unlock the potential within this vibrant hub of biotech and academic excellence for rare disease awareness, scientific progress and cross-sector collaboration.
At RAREsummmit19, the strength of this initiative and the power of a such a network to drive change will be apparent. The day will close with CamRARE putting its mission into practice during a cross-sector team challenge – an opportunity for all involved to have their say on the future of the UK Rare Disease Strategy.
• For more details and to book tickets visit https://camraredisease.org/summit-2019/
By Mike Scialom- mike.scialom@iliffemedia.co.uk
Published: 21:26, 09 December 2018 | Updated: 21:29, 09 December 2018
UNIQUEfeet at RAREfest
Rebecca Pender came from Glasgow to share her story at the recent RAREfest event, a world-first rare disease conference open to the public.
Her talk at the Guildhall was tremendously moving. In the Q&A, an audience member started crying as she tried to thank Rebecca for sharing with her story in a public place.
“I get strength from people like you,” she said. Another member of the public said joyously: “We’ve found our tribe.”
The theme of sharing stories that were previously out of the public eye was almost universal at RAREfest. Many families have suffered s they sought treatments – 95 per cent of rare diseases have not one single approved drug treatment. Even getting a diagnosis proved an Olympian task for Rebecca’s daughter, Hannah.
Afterwards I asked Rebecca, pictured, about her story.
RAREfest 2018 at the Guidlhall – Rebecca Pender from Glasgow consoles upset audience member
“Yes I made a member of the audience cry and she made me cry right back!” she said. Her daughter Hannah has 8p inverted duplication/deletion syndrome. This rare chromosomal anomaly is characterised clinically by mild to severe intellectual deficit, severe developmental delay (psychomotor and speech development), hypotonia/progressive hypertonia and severe orthopedic problems.
But perhaps worse than the disorder was the official response to it. “Hannah was nearly two when she was diagnosed,” explained Rebecca, “but I fought for her when she was born, she had a sacral dimple and an incredible cry, unlike anything I’d ever heard, very high-pitched.
“She was flat-footed and her toes overlapped and folded in on each other. She couldn’t hold her head up at six months. At 14 months she was still not sitting up so she had very, very delayed milestones.
“Nobody wanted to know. I was an over-protective mother [the authorities said], I was making things up. I had Munchausen by proxy, they said – that I was making up mental health problems, which then caused me to have mental health problems.
“I watched There She Goes, on BBC4 by Shaun Pye, that was about a child with a rare disease, David Tennant plays the dad. It was like a common story. Then, when we did get believed, we have to get her DLA (Disability Living Allowance) renewed annually as the condition ‘might change’.
Daniel Zeichner Dame Mary Archer at RAREfest
“It was a battle to get her into a school. We were homeless for 13 months as we were renting from a rogue landlord, we were made homeless 24 hours after my third daughter was born, and the council couldn’t find us somewhere suitable.
“It’s a constant battle to get services, to be included, and challenge people’s perception of her to be included.
“If I can come to events like this and speak publicly it can stop future families from going through what we have had to go through. It’s about changing the narrative, so it’s putting the person at the centre of the care process and getting rid of the hierarchy. Yes doctors have experience, but so do we. We need the children to survive and thrive. Hannah nearly dies as when she was poorly the doctors said it was viral and gave her Calpol. Situations like these need a proactive response not a reaction. If Hannah had had antibiotics it would have cost a lot less than 10 days in hospital – five of them in an emergency ward.”
By Mike Scialom- mike.scialom@iliffemedia.co.uk
Published: 16:52, 06 December 2018 | Updated: 17:31, 06 December 2018
Heartwarming, uplifting and informative, the world’s first-ever festival on rare diseases drew huge crowds to the Guildhall at the weekend (November 30/December 1).
RAREfest was organised by Cambridge Rare Disease Network (CamRARE) to “engage, educate and empower” those with rare diseases, their families, researchers, clinicians and support groups.
The event opened on Friday evening with introductions by Alastair Kent, OBE, the former director of Genetic Alliance UK.
“A few years ago it would not have been possible to have filled a hall like this,” he told the 200 attendees. “There are now 8,000 rare diseases affecting 3.5million people in the UK at some point in their lives. But it’s not just about a medical condition, we’re going to see some real stars to make us aware of the way that society can be changed for the better.”
First up was Abbi Brown, a CamRARE founder and Cambridge graduate born with osteogenesis imperfecta (OI), a genetic disorder which means her bones are extremely fragile and prone to breaks or fractures. Abbi related her experiences as a cox while a student, and described how easily her bones break. She did this with a sense of humour which has seen her perform at the Edinburgh Fringe.
Abbi was followed by a troupe of dancers, the children’s dance group Unique Feet. I wasn’t the only one to have a tear in my eye while watching their performance, they were so brave and powerful. In the interval I spoke with one of the dancers, Chloe King, aged 13, from Bar Hill, who was there with mum Jackie and dad Paul. Chloe has dyskerotosis congenita – a weakened immune system that doesn’t fight off infection. Like every rare disease sufferer here they and/or their families are very clued up about the mechanics of the disorder. Jackie explains that Chloe has a dysfunction of the telomere.
“The telomere is at the end of a chromosome and it’s like a shoelace, and the lace frays at the end and that’s the cells misbehaving.”
“My bone marrow gets low,” adds Chloe. “Half way through the day I get exhausted.”
Treatment options are increasing. Research is aimed at getting the body to restore the bone marrow more efficiently. The Kings are a lovely family and, like so many of those present, trying to imagine what they must have been through makes me tear up again.
RAREfest 2018 at the Guidlhall: From left are Adam Pearson, Dagmar Bennett, Paul King, Chloe King, 13, and Jackie King. Picture: Mike Scialom
Next on stage are Adam Pearson and Dagmar Bennett. Adam is a campaigner who suffers from neurofibromatosis, which causes excess skin to grow, especially but not exclusively facially. “It just happens,” he says of his condition. Dagmar is an artist who produced a sculpture of Adam as part of a course at the Centre for Appearance Research in Bristol: the work took seven months.
“I wanted to show Adam’s character,” she told the audience. “I was trying to get into the psychology, to use art to break down barriers.”
“We are bombarded every day by media images of how we should look,” noted Adam. “For people with disfigurement it can be absolutely paralysing.”
He has devoted his life to changing opinions. “As a campaigner I believe everything you do should serve a greater purpose.”
Adam and Dagmar’s powerful collective voice was followed James Risdon, who plays recorder. James’ rare eye condition, Leber’s Congenital Amaurosis, means he learns his repertoire from Braille. His music, with piano accompaniment, is accomplished and mesmerising, and is followed by another powerful voice, Michael McGrath. Michael is the first person to have been to both the North and South Poles despite having limb girdle muscular dystrophy (MD). Just as his body started shutting down on him, he raised his game and did things people said were impossible. His charity, Muscle Help Foundation, highlights what fighters many people with rare diseases are: Michael’s was an uplifting, life-affirming talk on an emotional and enchanting evening.
Saturday’s events were no less astounding, with talks about the incredible progress the medical sector is making to cure many rare diseases as new genomic data is integrated into medical practice. The main hall became a forum for stalls run by companies including Horizon Discovery, Abcam, No Isolation, The Wellcome MRC Cambridge Stem Cell Institute, LifeArc (the new name for Medical Research Council Technology), CamRARE, Heterogeneous, Pfizer and Microsoft.
RAREfest 2018 at the Guidlhall: BBC4 camerawoman Ila Mehrotra
I bumped into a BBC4 camerawoman, Ila Mehrotra, who’s part of a crew covering the festival, which had 600 visitors during the day.
“I’m working on a film about the history of genetics and particularly the context of eugenics,” said Ila.
Ila says eugenics started in the early 20th century before being highjacked by the Nazis in the 1930s.
“Eugenics, historically, was gene selection,” she said. “It was very much the preservation of the ‘most fit race’ which in the 1930s when it came out was the white race and scientists washed their hands of it completely.
“We’re looking at the positive aspects of how it can help people. We have Adam (Pearson) as a presenter and a black woman so we’re looking at it as a humane programme – it’s only just begun.”
Friday evening, RAREfest 2018 at the Guidlhall
Visitors are offered headphones to hear the talks while walking round the stalls. There’s a film festival which is packed out. The speakers I hear are wonderful, and the questions are very well informed. So who else is listening?
“Lots of people we’ve spoken to today are passers-by,” says Harriet Gridley, head of business development UK at No Isolation, a Norwegian firm which produces a robot, AV1, which can help children learn at home if they condition prevents them going to school. “They’re out doing their Christmas shopping. That’s wonderful because it means the topic is broadening out to the wider community.”
“It’s a mix of professionals and members of the public,” said architect Vaila Morrison, whose daughter’s rare disease is making her reconsider the built environment.
“It’s been brilliant, what a brilliant day,” said Abcam co-founder and deputy chairman Jonathan Milner later in the afternoon. Dr Milner was also at Dr Anna Middleton’s talk. Dr Middleton isfounder and Head of Society and Ethics Research at Connecting Science in the Wellcome Genome Campus. Her work has addressed the issue of how genomic data should be made available. So far the sector seems to consider it acceptable that a person’s genomic data should be made available to all research organisations, but the recent work by a Chinese scientist – gene-diting an embroy which was then born – has highlighted a difference of views. People are expected to be donating their genomic data to science but the industry is seekign ways to charge for the use they make of it. Intriguingly, differentnations see this issue in different lights. Dr Middleton’s study showed that Russians and Portuguese are happy for all genetic information to be shared for free: Britons, Australians and Germans, on the other hand, are less keen. The public is entitled to ask what would the information be used for? We’ve all seen what happened with Facebook, where an apparently innocuous sharing platform turned out to have a very dark underbelly. The issue of trust is crucial in what happens next, but one thing’s for sure: those attending this ground-breaking festival have found their tribe, and the support networks they need are now being built – all thanks to CamRARE.
The AV1 robot is designed and built by Norwegian firm No Isolation. It assists children with learning difficulties and can act as a companion to home-bound rare disease sufferers. Picture: Mike Scialom
Dr Sarah Leiter, a junior doctor Addenbrooke’s Hospital, lives with a rare condition – albinism – herself. She said: “RareFest proved a unique opportunity to educate the general public about rare disease but also to bring together local stakeholders. We hope that through this work we will improve the lives of those with rare disease.”
Jo Balfour, RAREfest and CamRARE events manager, said: “Our RAREfest launch event, with performances by those living with rare conditions, was widely applauded by those attending for its diversity, inclusion and for breaking down barriers. We’ve be delighted by the positive feedback on our main exhibition which exhibitors, speakers and attendees alike applauded for its excellent networking opportunities and for drawing in large numbers of the general public. The buzz and excitement over the weekend has been fabulous!”
The hope now is that RAREfest will be an annual event: the weekend certainly showed the demand is there.
Ann Middleton is head of society and ethics research, Connecting Science, Wellcome Genome Campus
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.